Appointment of North American IR Adviser

RNS Number : 2494Q

Oxford Cannabinoid Tech.Holdings

26 October 2021

 

26 October 2021

Oxford Cannabinoid Technologies Holdings plc

Appointment of North American Investor Relations Adviser

Oxford Cannabinoid Technologies Holdings plc ("OCTP" or "the Company"), the holding company of Oxford Cannabinoid Technologies Ltd ("OCT"), a pharmaceutical company developing prescription cannabinoid medicines for approval by key medicines regulatory agencies worldwide and targeting the US$ multi-billion pain market, is pleased to announce the appointment of Harbor Access LLC ("Harbor Access"), a US strategic investor relations adviser, based in Stamford, Connecticut.

Harbor Access will provide North American investor awareness support to OCTP, particularly in relation to the forthcoming admission to trading of the Company's shares on the OTC QB Market ("OTC QB", the mid-tier OTC Equity Market in the United States), under the ticker symbol "OCTHF".

Admission is expected to take place in November and is an important strategic step for the Company. It gives OTCP greater exposure to a much wider audience of potential investors by easing cross-border trading for the Company's US investors in addition to its London Stock Exchange Main Market Listing.

There is no capital-raise being conducted in conjunction with the application to trading on the OCT QB. OCTP's shares will continue to be traded on the London Stock Exchange under the ticker symbol "OCTP". Further information can be found at www.otcmarkets.com/learn/market-101.

Commenting on the appointment, OCTP's Chief Operating Officer, Clarissa Sowemimo-Coker, said: "As we move towards finalising our US share trading facility on the OTC QB Market, local investor knowledge and support are key to optimising our designation. Harbor Access has worked with numerous dual-quoted companies, and we look forward to having their support."

Jonathan Paterson, Managing Partner of Harbor Access, added: "We are excited to work with the team at OCTP. The Company's ongoing development of drug candidates for novel solutions for chronic pain management will offer an exciting new investment opportunity for the North American investment community."

As OCTP complete their OTC QB application process, Harbor Access has been retained for an initial six-month contract to support management with their application process and North American based investor relations.

The Directors of the Company accept responsibility for the content of this announcement.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature.

Enquiries:

Oxford Cannabinoid Technologies Holdings plc Dr John Lucas (CEO) Clarissa Sowemimo-Coker (COO)	[phone] [e-mail] [e-mail]
Walbrook PR Limited Paul Vann Nick Rome Nicholas Johnson	[phone] [phone] [e-mail]

Harbor Access LLC

Richard Leighton                                                        [e-mail]  

Jonathan Paterson                                                    [phone]

About Oxford Cannabinoid Technologies Holdings plc :

Oxford Cannabinoid Technologies Holdings plc ("OCTP" or the "Company") is the holding company of Oxford Cannabinoid Technologies Ltd ("OCT") (together the "Group"), a pharmaceutical company developing prescription cannabinoid medicines for approval by key medicines regulatory agencies worldwide and targeting the U$ multi-billion pain market. Cannabinoids are compounds found in the cannabis plant that have been shown to have a range of therapeutic effects on the body, including pain relief. The Group has a clearly defined path to commercialisation, revenues and growth. The Group is developing drug candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe them with confidence.

The Group's portfolio aims to balance risk, value and time to market, whilst ensuring market exclusivity around all its key activities. The Group's lead compound, OCT461201, is a highly potent and selective CB2 agonist and is being developed by OCT in a solid oral dosage form. OCT is conducting pre-clinical testing and development with pre-clinical trials scheduled for 2022. The Group's product pipeline also uses a balanced drug product strategy that employs both natural and synthetic compounds for the treatment of rare diseases and includes chemically modified phytocannabinoids with improved drug-like characteristics and a proprietary library of cannabinoids.

OCTP operates a partnership model with external academic and commercial partners, including the University of Oxford with whom OCT has had an umbrella research collaboration since 13 March 2018.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

 

END

 

 

NRAPPGWWUUPGUWQ